Aerie pharmaceuticals announces novel dry eye product candidate ar-15512 (trpm8 agonist) ophthalmic solution achieved statistical significance over multiple symptoms and signs in successful phase 2b clinical study for the treatment of dry eye disease

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results of its phase 2b clinical study, named comet-1, for ar-15512 (trpm8 agonist) (“ar-15512”) ophthalmic solution for the treatment of patients with dry eye diseas
AERI Ratings Summary
AERI Quant Ranking